Multitumor | Genomic Assays in the “Real” Oncology World — Part 1: Exploring the Role of Genomic Testing in Guiding Treatment for Patients with Advanced Breast, Colorectal and Prostate Cancers
Genomic Assays in the “Real” Oncology World — Part 1: Genomic
Assays and Colorectal Cancer — Featuring a roundtable discussion
with Drs Emmanuel S Antonarakis, Johanna Bendell, Ian E Krop and
Andrew McKenzie.
Multiplex Genomic Assays and Their Role in Therapeutic
Decision-Making
Case: A man in his mid-80s with metastatic
castration-resistant prostate cancer (mCRPC) whose disease
progressed through multiple therapies is found to have CD274
(PD-L1) amplification, microsatellite instability (MSI)-high status
and mutations in ATM and EGFR
Effect of CD274 amplification on response to immune checkpoint
inhibitors; activity of PARP inhibitors in patients with ATM
mutations
Advantages and limitations of multiplex genomic testing
Role of serial testing to identify variations in genomic
mutations or aberrations over time; potential benefit of liquid
next-generation sequencing (NGS) panels
Use of multiplex genomic assays by community oncologists and
implications for clinical practice
Optimal timing of genetic testing for patients diagnosed with
metastatic disease
Presentation (Dr McKenzie): Overview of
multiplex genomic assay methodology
Rationale for the use of serial testing and liquid assays to
identify variations in genomic mutations or aberrations over
time
Differentiating between germline and somatic mutations in
cancer tissue
Perspective on the use of tissue versus liquid biopsy for
genetic testing
Sensitivity of liquid biopsies in detecting tumor
mutations
Available data exploring the impact of NGS use on patient
outcomes
Selection of a multiplex genomic assay for detecting genetic
alterations
Implications of multiplex genomic assay results for therapeutic
decision-making
Comprehensive Genetic Profiling and Precision Medicine
for Metastatic Colorectal Cancer (mCRC)
Specific biomarkers and genetic alterations routinely evaluated
in clinical practice
Effects of up-front multiplex genomic assay testing on outcomes
for patients with mCRC
Response to immune checkpoint inhibitors in patients with
MSI-high mCRC (1:09:3s
Presentation (Dr Bendell): Biomarker
assessment in mCRC; role of multiplex testing
Actionable genetic alterations in mCRC; detection of BRAF and
HER2 mutations and implications for practice
Rationale and indications for the assessment of MSI and DNA
mismatch repair (MMR) status; emerging role of tumor mutational
burden
Role of liquid versus tumor biopsies for detecting genetic
alterations
MSI/MMR and tumor mutational burden as predictors of benefit
from immune checkpoint inhibitors
Emerging role for the assessment of neoantigen load
Case (Dr Bendell): A man in his mid-50s with
mCRC, Lynch syndrome and MSI-high status achieves a partial
response to pembrolizumab as second-line therapy
Case (Dr Bendell): A woman in her early 60s
with microsatellite stable mCRC and a BRAF V600E mutation receives
the combination of cetuximab, encorafenib and binimetinib after
disease progression on FOLFOXIRI/bevacizumab
Case (Dr Bendell): A man in his early 40s with
HER2-positive mCRC receives trastuzumab and pertuzumab on a
clinical trial after disease progression on FOLFIRI/bevacizumab and
attains a partial response
Novel HER2-targeted therapies under evaluation for patients
with mCRC and HER2 alterations
Analysis of the gut microbiome and strategies to enhance the
immune response to cancer
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.